All In Biotech

Drug Trial Radar · NCT03043651

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301

Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

48

Actual

Start

Jan 30, 2018

Primary completion

Mar 2, 2020

Study completion Mar 2, 2020

Sponsor

Lead sponsor
United TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who completed Study TDE-HF-301. This study provided long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Subject visits occurred at Baseline, Weeks 6, 12, 18, 24, and every 12 weeks thereafter until either oral treprostinil was commercially available to treat PH associated with HFpEF or the study was discontinued by the Sponsor. The Sponsor terminated Studies TDE-HF-301 and TDE-HF-302 on 14 October 2019 due to slow enrollment. Safety data from the final subject in Study TDE-HF-302 were recorded on 02 March 2020. Due to the lower than expected number of subjects enrolled, the planned secondary efficacy-related endpoints were not analyzed.

Conditions

  • Pulmonary Hypertension Associated With HFpEF

Interventions

  • Oral treprostinilDrug

    Sustained-release oral tablets for TID administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term Safety of Oral Treprostinil in Subjects With PH Associated With HFpEF for Subjects Who Completed Study TDE-HF-301Time frame: Baseline through study completion, up to approximately 25 months

Locations

82 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner University Medical Center Phoenix

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • VA Healthcare System of Greater Los Angeles

    Los Angeles, California

  • University of California Los Angeles Pulmonary Division

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California - Davis Medical Center

    Sacramento, California

  • Santa Barbara Cottage Hospital

    Santa Barbara, California

  • Aurora Denver Cardiology Associates

    Aurora, Colorado

  • University of Colorado Denver

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • South Denver Cardiology

    Littleton, Colorado

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Medical Faculty Associates, George Washington University

    Washington D.C., District of Columbia

  • Bay Area Cardiology Associates

    Brandon, Florida

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • St. Vincent's Lung, Sleep, and Critical Care Specialists

    Jacksonville, Florida

  • Central Florida Pulmonary Group, P.A.

    Orlando, Florida

  • Florida Hospital

    Orlando, Florida

  • University of South Florida ; Tampa General Hospital

    Tampa, Florida

  • Cleveland Clinic of Florida

    Weston, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • Piedmont Physicians Georgia Lung

    Austell, Georgia

  • WellStar Medical Group

    Marietta, Georgia

  • University of Illinois at Chicago Hospital

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • Advocate Christ Medical Center

    Oak Lawn, Illinois

  • OSF HealthCare

    Peoria, Illinois

  • Indiana University Health Methodist Research Institute, INC

    Indianapolis, Indiana

  • Community Heart and Vascular Hospital

    Indianapolis, Indiana

  • Saint Vincent Hospital and Health Services

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Iowa Heart Center

    West Des Moines, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Kentuckiana Pulmonary Associates

    Louisville, Kentucky

  • University of Louisville Physicians Outpatient Center

    Louisville, Kentucky

  • Chest Medicine Associates

    South Portland, Maine

  • Tufts Medical Center

    Boston, Massachusetts

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.